Literature DB >> 29782565

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.

Massimiliano Salati1, Cinzia Baldessari1, Bruna Cerbelli2, Andrea Botticelli3,4.   

Abstract

Entities:  

Year:  2018        PMID： 29782565      PMCID： PMC5943232          DOI： 10.21037/tlcr.2018.01.14

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

Review 1.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

2.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Authors:  Zhong-Yi Dong; Jia-Tao Zhang; Si-Yang Liu; Jian Su; Chao Zhang; Zhi Xie; Qing Zhou; Hai-Yan Tu; Chong-Rui Xu; Li-Xu Yan; Yu-Fa Li; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Oncoimmunology       Date:  2017-07-26       Impact factor: 8.110

3.  Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.

Authors:  Akito Hata; Nobuyuki Katakami; Shigeki Nanjo; Chiyuki Okuda; Reiko Kaji; Katsuhiro Masago; Shiro Fujita; Hiroshi Yoshida; Kota Zama; Yukihiro Imai; Yukio Hirata
Journal:  Lung Cancer       Date:  2017-07-20       Impact factor: 5.705

4.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

6.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

7.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

Review 10.  Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Authors:  Andrea Botticelli; Ilaria Zizzari; Federica Mazzuca; Paolo Antonio Ascierto; Lorenza Putignani; Luca Marchetti; Chiara Napoletano; Marianna Nuti; Paolo Marchetti
Journal:  Oncotarget       Date:  2017-01-31
View more
  11 in total

Review 1.  Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.

Authors:  M Sureda; E Calvo; J J Mata; V Escudero-Ortiz; E Martinez-Navarro; A Catalán; J Rebollo
Journal:  Clin Transl Oncol       Date:  2021-02-13       Impact factor: 3.405

Review 2.  Signal pathways and precision therapy of small-cell lung cancer.

Authors:  Min Yuan; Yu Zhao; Hendrik-Tobias Arkenau; Tongnei Lao; Li Chu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2022-06-15

3.  A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

Authors:  Andrea Botticelli; Massimiliano Salati; Francesca Romana Di Pietro; Lidia Strigari; Bruna Cerbelli; Ilaria Grazia Zizzari; Raffaele Giusti; Marco Mazzotta; Federica Mazzuca; Michela Roberto; Patrizia Vici; Laura Pizzuti; Marianna Nuti; Paolo Marchetti
Journal:  J Transl Med       Date:  2019-03-27       Impact factor: 5.531

4.  Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance.

Authors:  Peter Kim Moon; Stephanie Tran; Paras Singh Minhas
Journal:  J Transl Med       Date:  2019-01-18       Impact factor: 5.531

5.  Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review.

Authors:  Wei Li; Hao Wang; Bin Chen; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Juan Deng; Yayi He; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2020-04

6.  Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.

Authors:  Andrea Botticelli; Alessio Cirillo; Lidia Strigari; Filippo Valentini; Bruna Cerbelli; Simone Scagnoli; Edoardo Cerbelli; Ilaria Grazia Zizzari; Carlo Della Rocca; Giulia D'Amati; Antonella Polimeni; Marianna Nuti; Marco Carlo Merlano; Silvia Mezi; Paolo Marchetti
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

7.  Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Authors:  Andrea Botticelli; Bruna Cerbelli; Luana Lionetto; Ilaria Zizzari; Massimiliano Salati; Annalinda Pisano; Mazzuca Federica; Maurizio Simmaco; Marianna Nuti; Paolo Marchetti
Journal:  J Transl Med       Date:  2018-08-06       Impact factor: 5.531

8.  Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.

Authors:  Andrea Botticelli; Silvia Mezi; Giulia Pomati; Bruna Cerbelli; Edoardo Cerbelli; Michela Roberto; Raffaele Giusti; Alessio Cortellini; Luana Lionetto; Simone Scagnoli; Ilaria Grazia Zizzari; Marianna Nuti; Maurizio Simmaco; Paolo Marchetti
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

9.  Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases.

Authors:  Juan Zhou; Fei Zhou; Xiangling Chu; Jing Zhao; Yan Wu; Wencheng Zhao; Chuan Xu; Chunxia Su
Journal:  Transl Lung Cancer Res       Date:  2020-04

10.  A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.

Authors:  Xiaoling Shang; Jianxiang Shi; Xiaohui Wang; Chenglong Zhao; Haining Yu; Haiyong Wang
Journal:  Cancer Med       Date:  2021-07-31       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.